Together, the different patient numbers, genetic profiles, and EGFR-TKIs may be the reasons why PD-L1 expression affected the prognosis of EGFR-mutated NSCLC patients in the two previous studies but not in our study. This evidence concerns the gene CD274 and non-small cell lung carcinoma.